Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with PDE5i for the treatment of erectile dysfunction.
Lead Product(s): Bremelanotide Acetate,Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Vyleesi
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2024
Details:
Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.
Lead Product(s): Bremelanotide Acetate,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: Vyleesi
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2024
Details:
PT-141 (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.
Lead Product(s): Bremelanotide Acetate,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: PT-141
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2024
Details:
PL9643 is a novel selectively binder to melanocortin receptors that acts as MC1/MC5 receptor agonist drug candidate, which is being evaluated for the treatment of patients with Dry Eye Disease.
Lead Product(s): PL9643
Therapeutic Area: Ophthalmology Product Name: PL9643
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Cosette Pharma
Deal Size: $171.0 million Upfront Cash: $12.0 million
Deal Type: Acquisition January 03, 2024
Details:
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Cosette Pharma
Deal Size: $171.0 million Upfront Cash: $12.0 million
Deal Type: Divestment January 02, 2024
Details:
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Cosette Pharma
Deal Size: $171.0 million Upfront Cash: $12.0 million
Deal Type: Divestment December 20, 2023
Details:
PL9643 ophthalmic solution (topical eye drops) which is act as the melanocortin receptor agonists investigated for the treatment of patients with dry eye disease.
Lead Product(s): PL9643
Therapeutic Area: Ophthalmology Product Name: PL9643
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
Vyleesi (bremelanotide injection) is a melanocortin receptor (MCR) agonist that is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Psychiatry/Psychology Product Name: Vyleesi
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
Vyleesi (bremelanotide injection) is a melanocortin receptor (MCR) agonist that is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Lead Product(s): Bremelanotide Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Vyleesi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023